CCCC

C4 Therapeutics INC

+$68.7M

Net Activity

Institutions Holding

123

Popularity Rank

#4018

Avg Weight

0.08%

Total Value

$221.6M

Ownership Trend

123 institutions currently hold CCCC, with 73 net buyers and 42 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Majority Increased

Based on recent trading activity

Net Selling Institutions

42

Net Buying Institutions

73

Key Holders

View all 123 holding institutions

Quarterly Activity

Recent Activity

+$110.2M

Total Buy Value

$65.0M

Total Sell Value

New buy31
Trim30
Add42
Sold out12

73

Net Buyers

42

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding C4 THERAPEUTICS INC (CCCC)?
Major stakeholders currently include Morgan Stanley ($23.9M), Ra Capital Management, L.p. ($21.0M), Bain Capital Life Sciences Investors, LLC ($18.9M). Based on the latest 13F filings, there are a total of 123 tracked investment funds and institutions maintaining positions in CCCC.
What is the overall institutional sentiment toward CCCC recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $68.7M, driven by 73 managers accumulating shares while 42 reduced their exposure.
Which institutions have been selling or reducing their CCCC positions?
In the latest period, 30 funds trimmed their holdings, and 12 managers completely exited their positions. The aggregate reported sell value was $65.0M.
Are there any notable investors adding CCCC to their portfolios?
Yes, buying activity remains notable. 31 institutions opened new positions in {ticker}, and 42 existing holders added to their shares. The total reported buy value for the quarter amounted to $110.2M.

Related Stocks